Latest:
Dr. Bates on Stimulating the Immune System With Nanoparticles in RCC
Paula J. Bates, PhD, discusses the use of nanoparticles to stimulate the immune system in renal cell carcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Paulo Marcelo Hoff, MD, PhD
Latest:
Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRC
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).
Pei-Chun McGregor, MD
Latest:
Dr. McGregor on the Goals of ADT in Prostate Cancer
Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the goals of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.
Peter A. Johnstone, MD
Latest:
Dr. Johnstone on Immediate Salvage Therapy for Prostate Cancer
Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.
Peter A. Jones, PhD, DSc
Latest:
USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical Practice
Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.
Peter Black, MD
Latest:
Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer
Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.